CD274 and neoplasm: Accordingly, considering the results of tumor assessment in terms of MSI/MMR status, T-cell-inflamed GEP and PD-L1 expression, coupled with using TMB for predicting pembrolizumab efficacy, may still be important even for this regimen in case of switching to pembrolizumab monotherapy.